Ammonium chloride enhances cisplatin cytotoxicity through DNA double-strand breaks in human cervical cancer cells

Xu,Ye; Wang,Ning; Ding,Yan; Wang,Chunyan; Yu,Yang; Liu,Shibing; Wang,Xiaojun; Li,Zhixin

doi:10.3892/or.2013.2554

Ammonium chloride enhances cisplatin cytotoxicity through DNA double-strand breaks in human cervical cancer cells

Authors:
- Ye Xu
- Ning Wang
- Yan Ding
- Chunyan Wang
- Yang Yu
- Shibing Liu
- Xiaojun Wang
- Zhixin Li
View Affiliations

Affiliations: Medical Research Laboratory, Jilin Medical College, Jilin 132013, P.R. China, Clinical College, Jilin Medical College, Jilin 132013, P.R. China, Department of Histology and Embryology, Jilin Medical College, Jilin 132013, P.R. China
Published online on: June 20, 2013 https://doi.org/10.3892/or.2013.2554
Pages: 1195-1200

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Cisplatin (cis-diamminedichloroplatinum II, CDDP) acts as a therapeutic agent by initiating cellular apoptosis. However, side-effects and drug resistance limit the clinical use of cisplatin. Numerous studies have focused on the drug-target interactions, cellular pharmacology and pharmacokinetics of cisplatin. Newly developed treatment strategies are needed in order to be used in combination with cisplatin, with the aim to minimize toxicity and to circumvent cisplatin resistance. Ammonium chloride (NH4Cl) is widely used in various areas, but its use as a combination agent with cisplatin for the treatment of cancer cells has not been previously reported. In the present study, we showed that NH4Cl could be potentially used as an effective agent in cisplatin combination treatment of HeLa human cervical cancer (HCC) cells. Cisplatin was found to inhibit cell growth, as well as to induce cell apoptosis and DNA double-strand breaks. In addition, treatment with NH4Cl increased the rate of cell apoptosis and the activation of caspase-3. Particularly, we found that NH4Cl treatment increased cisplatin‑induced phosphorylation of H2AX. In conclusion, our data indicate that NH4Cl enhances cisplatin cytotoxicity through increased DNA damage in HeLa HCC cells.

View Figures

View References

1	Loehrer PJ and Einhorn LH: Drugs five years later. Cisplatin Ann Intern Med. 100:704–713. 1984.PubMed/NCBI
2	WoŸniak K and Błasiak J: Recognition and repair of DNA-cisplatin adducts. Acta Biochim Pol. 49:583–596. 2002.
3	Reedijk J: New clues for platinum antitumor chemistry: kinetically controlled metal binding to DNA. Proc Natl Acad Sci USA. 100:3611–3616. 2003. View Article : Google Scholar : PubMed/NCBI
4	Basu A and Krishnamurthy S: Cellular responses to cisplatin-induced DNA damage. J Nucleic Acids. 2010:2013672010. View Article : Google Scholar
5	Liu D, Yang Y, Liu Q and Wang J: Inhibition of autophagy by 3-MA potentiates cisplatin-induced apoptosis in esophageal squamous cell carcinoma cells. Med Oncol. 28:105–111. 2011. View Article : Google Scholar : PubMed/NCBI
6	Kang R, Wang ZH, Wang BQ, et al: Inhibition of autophagy-potentiated chemosensitivity to cisplatin in laryngeal cancer Hep-2 cells. Am J Otolaryngol. 33:678–684. 2012. View Article : Google Scholar : PubMed/NCBI
7	Xu Y, Yu H, Qin H, et al: Inhibition of autophagy enhances cisplatin cytotoxicity through endoplasmic reticulum stress in human cervical cancer cells. Cancer Lett. 314:232–243. 2012. View Article : Google Scholar
8	Kimura T, Takabatake Y, Takahashi A and Isaka Y: Chloroquine in cancer therapy: a double-edged sword of autophagy. Cancer Res. 73:3–7. 2013. View Article : Google Scholar : PubMed/NCBI
9	Elstrom RL, Andemariam B, Martin P, et al: Bortezomib in combination with rituximab, dexamethasone, ifosfamide, cisplatin and etoposide chemoimmunotherapy in patients with relapsed and primary refractory diffuse large B-cell lymphoma. Leuk Lymphoma. 53:1469–1473. 2012. View Article : Google Scholar
10	Kubicek GJ, Axelrod RS, Machtay M, et al: Phase I trial using the proteasome inhibitor bortezomib and concurrent chemoradiotherapy for head-and-neck malignancies. Int J Radiat Oncol Biol Phys. 83:1192–1197. 2012. View Article : Google Scholar : PubMed/NCBI
11	Ong PS, Wang XQ, Lin HS, Chan SY and Ho PC: Synergistic effects of suberoylanilide hydroxamic acid combined with cisplatin causing cell cycle arrest independent apoptosis in platinum-resistant ovarian cancer cells. Int J Oncol. 40:1705–1713. 2012.
12	Jin KL, Park JY, Noh EJ, Hoe KL, Lee JH, Kim JH and Nam JH: The effect of combined treatment with cisplatin and histone deacetylase inhibitors on HeLa cells. J Gynecol Oncol. 21:262–268. 2010. View Article : Google Scholar : PubMed/NCBI
13	Mathew JT and Bio LL: Injectable ammonium chloride used enterally for the treatment of persistent metabolic alkalosis in three pediatric patients. J Pediatr Pharmacol Ther. 17:98–103. 2012.PubMed/NCBI
14	Kawai A, Uchiyama H, Takano S, Nakamura N and Ohkuma S: Autophagosome-lysosome fusion depends on the pH in acidic compartments in CHO cells. Autophagy. 3:154–157. 2007. View Article : Google Scholar : PubMed/NCBI
15	Yang YP, Liang ZQ, Gao B, Jia YL and Qin ZH: Dynamic effects of autophagy on arsenic trioxide-induced death of human leukemia cell line HL60 cells. Acta Pharmacol Sin. 29:123–134. 2008. View Article : Google Scholar : PubMed/NCBI
16	Yu C, Huang X, Xu Y, et al: Lysosome dysfunction enhances oxidative stress-induced apoptosis through ubiquitinated protein accumulation in Hela cells. Anat Rec (Hoboken). 296:31–39. 2013. View Article : Google Scholar
17	Safirstein R, Winston J, Goldstein M, Moel D, Dikman S and Guttenplan J: Cisplatin nephrotoxicity. Am J Kidney Dis. 8:356–367. 1986. View Article : Google Scholar
18	Choudhury D and Ahmed Z: Drug-associated renal dysfunction and injury. Nat Clin Pract Nephrol. 2:80–91. 2006. View Article : Google Scholar : PubMed/NCBI
19	Alexander S, Swatson WS and Alexander H: Pharmacogenetics of resistance to cisplatin and other anticancer drugs and the role of sphingolipid metabolism. Methods Mol Biol. 983:185–204. 2013. View Article : Google Scholar : PubMed/NCBI
20	Sherman SE, Gibson D, Wang AH and Lippard SJ: X-ray structure of the major adduct of the anticancer drug cisplatin with DNA: cis-[Pt(NH₃)₂{d(pGpG)}]. Science. 230:412–417. 1985.
21	Chaney SG, Campbell SL, Bassett E and Wu Y: Recognition and processing of cisplatin- and oxaliplatin-DNA adducts. Crit Rev Oncol Hematol. 53:3–11. 2005. View Article : Google Scholar : PubMed/NCBI
22	Rebillard A, Lagadic-Gossmann D and Dimanche-Boitrel MT: Cisplatin cytotoxicity: DNA and plasma membrane targets. Curr Med Chem. 15:2656–2663. 2008. View Article : Google Scholar : PubMed/NCBI
23	Jiang M, Wang CY, Huang S, Yang T and Dong Z: Cisplatin-induced apoptosis in p53-deficient renal cells via the intrinsic mitochondrial pathway. Am J Physiol Renal Physiol. 296:F983–F993. 2009. View Article : Google Scholar : PubMed/NCBI
24	Zhu J, Yang Y and Wu J: Bcl-2 cleavages at two adjacent sites by different caspases promote cisplatin-induced apoptosis. Cell Res. 17:441–448. 2007.PubMed/NCBI
25	Sharma H, Sen S and Singh N: Molecular pathways in the chemosensitization of cisplatin by quercetin in human head and neck cancer. Cancer Biol Ther. 4:949–955. 2005. View Article : Google Scholar : PubMed/NCBI
26	Wei Q, Dong G, Franklin J and Dong Z: The pathological role of Bax in cisplatin nephrotoxicity. Kidney Int. 72:53–62. 2007. View Article : Google Scholar : PubMed/NCBI
27	Peyrou M, Hanna PE and Cribb AE: Cisplatin, gentamicin, and p-aminophenol induce markers of endoplasmic reticulum stress in the rat kidneys. Toxicol Sci. 99:346–353. 2007. View Article : Google Scholar : PubMed/NCBI
28	Hotchkiss RS, Strasser A, McDunn JE and Swanson PE: Cell death. N Engl J Med. 361:1570–1583. 2009. View Article : Google Scholar : PubMed/NCBI
29	Slee EA, Adrain C and Martin SJ: Executioner caspase-3, -6, and -7 perform distinct, non-redundant roles during the demolition phase of apoptosis. J Biol Chem. 276:7320–7326. 2001. View Article : Google Scholar : PubMed/NCBI
30	Olive PL and Banáth JP: Kinetics of H₂AX phosphorylation after exposure to cisplatin. Cytometry B Clin Cytom. 76:79–90. 2009.
31	Fuertesa MA, Castillab J, Alonsoa C and Perez JM: Cisplatin biochemical mechanism of action: from cytotoxicity to induction of cell death through interconnections between apoptotic and necrotic pathways. Curr Med Chem. 10:257–266. 2003. View Article : Google Scholar : PubMed/NCBI
32	Gonzalez VM, Fuertes MA, Alonso C and Perez JM: Is cisplatin-induced cell death always produced by apoptosis? Mol Pharmacol. 59:657–663. 2001.PubMed/NCBI
33	Perez RP: Cellular and molecular determinants of cisplatin resistance. Eur J Cancer. 34:1535–1542. 1998. View Article : Google Scholar : PubMed/NCBI
34	Mandic A, Hansson J, Linder S and Shoshan MC: Cisplatin induces endoplasmic reticulum stress and nucleus-independent apoptotic signaling. J Biol Chem. 278:9100–9106. 2003. View Article : Google Scholar : PubMed/NCBI
35	Ruiz A, Matute C and Alberdi E: Intracellular Ca²⁺ release through ryanodine receptors contributes to AMPA receptor-mediated mitochondrial dysfunction and ER stress in oligodendrocytes. Cell Death Dis. 1:e542010.
36	Lee JW, Kim WH, Yeo J and Jung MH: ER stress is implicated in mitochondrial dysfunction-induced apoptosis of pancreatic beta cells. Mol Cells. 30:545–549. 2010. View Article : Google Scholar : PubMed/NCBI
37	Takemoto K, Miyata S, Takamura H, Katayama T and Tohyama M: Mitochondrial TRAP1 regulates the unfolded protein response in the endoplasmic reticulum. Neurochem Int. 58:880–887. 2011. View Article : Google Scholar : PubMed/NCBI
38	Haghighat N, McCandless DW and Geraminegad P: The effect of ammonium chloride on metabolism of primary neurons and neuroblastoma cells in vitro. Metab Brain Dis. 15:151–162. 2000. View Article : Google Scholar : PubMed/NCBI